

Oligometastasis and stereotactic body radiotherapy in the era of systemic targeted therapies and immunotherapy

9th December 2021

Course Directors

Prof. Roberto Orecchia

Prof. Barbara A. Jereczek-Fossa

Scientific Directors

Dr. Giulia Marvaso

Dr. Matteo Pepa



Introduction

The oligo-metastatic state is conventionally an intermediate state that, even though the disease must be considered systemic, may benefit from local treatments. Evidence of the benefit from aggressive local therapies comes from improved survival in retrospective series and randomised trials.

The advent of more sophisticated imaging techniques has allowed to diagnose earlier and deliver progressively higher doses to small target volumes with ablative intent stereotactic body radiation therapy (SBRT).

This webinar aims to highlight the role of SBRT in oligometastatic patients and in combination with chemotherapy, target therapies and immunotherapy in the most common diseases (breast, lung, prostate).

After a brief introduction of all the aspects of the oligometastatic setting, the combination scenario of drugs and SBRT will be presented from two main points of view: the Radiation oncologist's vs the Medical oncologist's one.

Programme

- 15.00 Welcome and introduction
R. Orecchia
- 15.10 The RADIOSA trial: an overview
B. A. Jereczek-Fossa
- 15.20 The RADIOSA trial: biological aspects
M. Zaffaroni
- 15.30 Characterisation and classification of oligometastatic disease
M. Guckenberger
- 15:45 Imaging in oligometastatic cancers
G. Petralia
- 16:00 Positron Emission Tomography (PET) imaging in oligometastatic cancers
F. Ceci
- 16.15 Radio-immunotherapy: the medical oncologist's point of view
P. Queirolo

Session 1 - RO vs MO: PROSTATE

Chair: Vincenzo Valentini, Stefano Arcangeli

- 16.30 Oligorecurrent prostate cancer – where are we now?
G. Marvaso
- 16.45 Combination of radiotherapy and new drugs in oligometastatic prostate cancer: the medical oncologist's point of view
U. Vogl
- 17.00 Discussion

Session 2 - RO vs MO: LUNG

Chair: Gaia Piperno, Filippo Alongi

17.15 Oligometastatic lung cancer – state of art
S. Siva

17.30 Combination of radiotherapy and new drugs in oligometastatic lung cancer: the medical oncologist's point of view
A. Passaro

17.45 Discussion

Session 3 - RO vs MO: BREAST

Chair: Maria Carmen De Santis, Maria Cristina Leonardi

18.00 Oligometastatic breast cancer
I. Meattini

18.15 Combination of radiotherapy and new drugs in oligometastatic breast cancer: the medical oncologist's point of view
C. Criscitiello

18.30 Discussion

18.45-19.10 Closing remarks – B. A. Jereczek-Fossa

Course Directors

Roberto Orecchia

Scientific Director, IEO Milan, Italy

Barbara Alicja Jereczek-Fossa

Director, Division of Radiotherapy, IEO Milan, Italy

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

Scientific Directors

Giulia Marvaso

Division of Radiotherapy, IEO European Institute of Oncology IRCCS Milan, Italy

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy

Matteo Pepa

Division of Radiotherapy, IEO European Institute of Oncology IRCCS Milan, Italy

Faculty

Filippo Alongi

Advanced Radiation Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar Di Valpolicella, Italy

University of Brescia, Brescia, Italy

Stefano Arcangeli

Department of Radiation Oncology, School of Medicine and Surgery-University of Milan Bicocca, Milan, Italy

Francesco Ceci

Division of Nuclear Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy

Carmen Criscitiello

Division of Early Drug Development for Innovative Therapies, IEO, Milan, Italy

Department of Oncology and Haemato-Oncology, University of Milan, Italy

Maria Carmen De Santis

Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy

Matthias Guckenberger

Department of Radiation Oncology and Competence Center for Palliative Care, University Hospital
Zurich, Switzerland

Maria Cristina Leonardi

Division of Radiotherapy, IEO, Milan, Italy

Icro Meattini

Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Italy
Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence,
Italy

Antonio Passaro

Division of Thoracic Oncology, IEO, Milan, Italy

Giuseppe Petralia

Department of Oncology and Hemato-Oncology, University of Milan, Italy
Precision Imaging and Research Unit, Department of Medical Imaging and Radiation Sciences, IEO Milan,
Italy

Gaia Piperno

Division of Radiotherapy, IEO European Institute of Oncology IRCCS Milan, Italy

Paola Queirolo

Division of Medical Oncology for Melanoma, Sarcoma and Rare Tumors, IEO Milan, Italy

Shankar Siva

Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Victoria, Australia

Vincenzo Valentini

UOC of Oncological Radiotherapy, Department of Imaging Diagnostics, Oncological Radiotherapy and
Haematology, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
Institute of Radiology, Catholic University of the Sacred Heart, Rome, Italy

Ursula Vogl

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Mattia Zaffaroni

Division of Radiotherapy, IEO Milan, Italy

Acknowledgments



The webinar is fully funded by Associazione Italiana per la Ricerca sul Cancro (AIRC), project IG-22159 “Radioablation + hormonotherapy for prostate cancer oligorecurrences (RADIO-SA trial): potential of imaging and biology”, registered at ClinicalTrials.gov (NCT03940235), approved by the Ethics Committee of IRCCS Istituto Europeo di Oncologia and Centro Cardiologico Monzino (IEO-997).

Registration's fee

Registration is free of charge subject to availability.

Online registrations

You can register online at: www.ieoeducationlive.it

By selecting the event you are interested in and follow the instructions.

Registrations will automatically be accepted in order of arrival, subject to availability.

Certificate of attendance and CME credits

The course is accredited ECM (JUST FOR ITALIAN PARTICIPANTS) for Medical Physicists, Psychologist, Radiotherapy Technicians, Oncologists, Radioterapists, Radiodiagnostics.

Provider IEO ID 207-336808

Credits: 6

We remind you that in order to be entitled to ECM training credits it is compulsory to: attend 90% of the training hours, fill in the event evaluation questionnaire, take and pass the learning test.

The certificate of attendance will be sent by e-mail a few days after the end of the course, while the certificate containing the CME credits will be downloaded directly from the website after correctly completing the online questionnaire.

Please note that the CME certificate of participation does not constitute a qualification for the exercise of the activities covered.

Organizational Secretariat

MZ Congressi srl

Via Carlo Farini,81

20159 Milano

Tel: +393421863400

Mail: ieoedu.eventi@ieo.it